BioCardia, Inc. 8-K

What Happened
On May 28, 2026, BioCardia, Inc. announced that Japan’s PMDA (Pharmaceutical and Medical Device Agency) issued a Consultation Record indicating support for a regulatory submission for the CardiAMP® autologous cell therapy to treat ischemic heart failure with reduced ejection fraction (HFrEF). The PMDA said the positive trial outcomes were credible and agreed on remaining questions to address before and as part of the submission. The Company reported these results were based on its three completed clinical trials and a presentation by Dr. Raval on behalf of the CardiAMP CMI Investigators. A copy of the press release is attached as Exhibit 99.1 to the 8-K.

Key Details

• PMDA estimated an initial eligible patient population of about 20,000 out of ~300,000 HFrEF patients in Japan.
• PMDA requested BioCardia confirm enrolled patients were on guideline-directed medical therapy (GDMT) and not eligible for revascularization, and provide details for each incidence of all-cause death, heart transplant or LVAD implantation.
• Clinical results presented: no treatment-emergent major adverse cardiac events; average increase in exercise tolerance of 179 seconds sustained to two years; angina episodes reduced by ~82% at six months.
• The disclosure is a Regulation FD announcement furnished in an 8-K (filed 2026-05-28); press release is Exhibit 99.1.

Why It Matters
PMDA alignment on the submission path is a meaningful regulatory step for BioCardia in Japan and could reduce approval uncertainty if the company satisfactorily addresses the remaining PMDA requests. The cited safety and efficacy signals (no major treatment-emergent cardiac events, durable exercise improvement, large angina reduction) support the therapy’s clinical value. However, the PMDA’s requests mean further documentation and case-level detail are required before approval, so regulatory and commercial outcomes are not guaranteed. Investors should view this as progress on the Japan regulatory pathway, not as an approval or revenue event.